全文获取类型
收费全文 | 2441篇 |
免费 | 355篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 105篇 |
妇产科学 | 37篇 |
基础医学 | 180篇 |
口腔科学 | 27篇 |
临床医学 | 321篇 |
内科学 | 750篇 |
皮肤病学 | 63篇 |
神经病学 | 227篇 |
特种医学 | 379篇 |
外科学 | 281篇 |
综合类 | 34篇 |
预防医学 | 84篇 |
眼科学 | 17篇 |
药学 | 99篇 |
中国医学 | 1篇 |
肿瘤学 | 216篇 |
出版年
2023年 | 54篇 |
2022年 | 14篇 |
2021年 | 41篇 |
2020年 | 104篇 |
2019年 | 26篇 |
2018年 | 111篇 |
2017年 | 82篇 |
2016年 | 78篇 |
2015年 | 81篇 |
2014年 | 124篇 |
2013年 | 139篇 |
2012年 | 81篇 |
2011年 | 73篇 |
2010年 | 97篇 |
2009年 | 126篇 |
2008年 | 78篇 |
2007年 | 78篇 |
2006年 | 77篇 |
2005年 | 75篇 |
2004年 | 72篇 |
2003年 | 47篇 |
2002年 | 57篇 |
2001年 | 61篇 |
2000年 | 43篇 |
1999年 | 50篇 |
1998年 | 95篇 |
1997年 | 104篇 |
1996年 | 92篇 |
1995年 | 76篇 |
1994年 | 57篇 |
1993年 | 57篇 |
1992年 | 39篇 |
1991年 | 31篇 |
1990年 | 31篇 |
1989年 | 59篇 |
1988年 | 46篇 |
1987年 | 32篇 |
1986年 | 23篇 |
1985年 | 26篇 |
1984年 | 18篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1977年 | 14篇 |
1976年 | 11篇 |
1975年 | 9篇 |
1971年 | 8篇 |
排序方式: 共有2835条查询结果,搜索用时 421 毫秒
1.
2.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
3.
4.
5.
6.
7.
U. Meyding-Lamadé K. Rieke D. Krieger W. Hacke Michael Forsting Klaus Sartor Christian Sommer 《Journal of neurology》1995,242(5):335-343
Acute ischaemia of the vertebrobasilar circulation leads to a variety of clinical manifestation and is mostly due to cardiogenic or artery-to-artery embolism. We describe four neurological emergency situations involving vertebrobasilar artery aclusion of other origins: basilar migraine, extrinsic compression by rheumatoid inflammatory tissue, generalized vasculitis in subacute rheumatic fever and basilar artery dissection. The differential diagnosis of acute vertebrobasilar artery occlusion may have an important impact on patient management. 相似文献
8.
C. J. Bowden W. D. Figg N. A. Dawson O. Sartor R. J. Bitton M. S. Weinberger Donna Headlee Eddie Reed C. E. Myers M. R. Cooper 《Cancer chemotherapy and pharmacology》1996,39(1-2):1-8
Introduction: Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis,
but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent. Objective: This clinical trial of suramin was undertaken as a phase I/II study in patients with hormone-refractory prostate cancer,
with the hypothesis that the intensity of therapy with suramin could be increased significantly if measures were undertaken
to maintain the plasma concentrations of the drug under 300 μg/ml. Methods: We report the clinical results of this trial, wherein patients were treated at three different targeted plasma suramin concentrations
(275, 215 and 175 μg/ml) for varying periods of time (2, 4 or 8 weeks), with delivery of the drug by continuous intravenous
infusion. Results: The major toxicity observed in this trial was neurologic, consisting of a motor and sensory peripheral neuropathy that resulted
in both paresis and paralysis of the limbs. Nearly all of this severe (CTEP grade III, IV) neurologic toxicity was observed
in the patients treated at a plasma suramin concentration of 275 μg/ml for 4 or more weeks. A single patient treated at 215 μg/ml
for 8 weeks developed moderate (CTEP grade III) proximal lower extremity weakness, and no patient treated at 175 μg/ml developed
this toxicity. The second most common toxicity observed was infection of the central venous catheter. The overall response
rate for all of the evaluable patients was 17% (13 of 75 patients). In addition, prostate-specific antigen (PSA)-defined responses
were observed in six patients receiving therapy at 175 μg/ml, but these responses were confounded by cessation of therapy
with flutamide during suramin treatment. Conclusions: In summary, although plasma suramin concentrations were maintained below 300 μg/ml, neurologic toxicity nonetheless occurred
with high frequency in patients treated at 275 μg/ml for 4 or more weeks. Therapy at 215 and 175 μg/ml was in general well
tolerated, but central venous catheter-related infection, as well as the inconvenience and expense of continuous infusional
therapy, make this method of drug delivery impractical. Only moderate antitumor activity was observed during this trial, but
it is possible that both continuation of flutamide and flutamide withdrawal during suramin therapy confounded the assessment
of suramin’s activity in hormone-refractory prostate cancer.
Received: 9 June 1995/Accepted: 18 March 1996 相似文献
9.
10.